Cargando…
Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
The global development of a biosimilar product is a methodologically complex affair, lined with potential design pitfalls and operational missteps to be avoided. Without careful attention to experimental design and meticulous execution, a development programme may fail to demonstrate equivalence, as...
Autores principales: | Lai, Zhihong, La Noce, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746581/ https://www.ncbi.nlm.nih.gov/pubmed/26870392 http://dx.doi.org/10.1136/rmdopen-2015-000154 |
Ejemplares similares
-
Biosimilars: what do patients need to consider?
por: Skingle, Diana
Publicado: (2015) -
Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?
por: Toussirot, Eric, et al.
Publicado: (2017) -
Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis
por: Lindström, Ulf, et al.
Publicado: (2019) -
Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
por: Stajszczyk, Marcin, et al.
Publicado: (2023) -
AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)